retatrutide approved in other countries ESC 2024: improves lipid and cardiovascular risk profile Phase II trial Retatrutide (LY3437943) | GCGR/GIPR/GLP-1R Agonist
Description
Instead of escalating on a fixed schedule, you only increase when weight loss has genuinely stalled
Long-term safety and efficacy of fasiglifam (TAK-875), a G-protein-coupled receptor 40 agonist, as monotherapy and combination therapy in Japanese patients with type 2 diabetes: a 52-week open-label phase III study
While semaglutide GLP-1 is a valuable tool for weight management, its important to set realistic expectations
doi: 10.1016/S1542-3565(24)00910-8 FDA
A common mistake: treating symptoms instead of causes One of the reasons some people repeatedly regain weight is that they focus entirely on visible outcomes
